

LEENLIFE PHARMA INTERNATIONAL INC.

(Formerly SPT Sulphur Polymer Technologies Inc.)

Condensed Interim Financial Statements

**Nine Months Ended
December 31, 2015**

	Page
Notice of No Auditor Review of Condensed Interim Financial Statements	2
Condensed Interim Statements of Financial Position	3
Condensed Interim Statements of Loss and Comprehensive Loss	4
Condensed Interim Statements of Changes in Shareholders' Deficiency	5
Condensed Interim Statements of Cash Flows	6
Notes to the Condensed Interim Financial Statements	7 - 19

LEENLIFE PHARMA INTERNATIONAL INC.

(Formerly SPT Sulphur Polymer Technologies Inc.)

December 31, 2015

**NOTICE OF NO AUDITOR REVIEW OF CONDENSED INTERIM
FINANCIAL STATEMENTS**

Under National Instrument 51-102, Part 4, subsection 4.3(3) (a), if an auditor has not performed a review of the condensed interim consolidated financial statements, they must be accompanied by a notice indicating that the financial statements have not been reviewed by an auditor.

The Company's independent auditor has not performed a review of these financial statements in accordance with standards established by the Canadian Institute of Chartered Accountants for a review of interim financial statements by an entity's auditor.

LEENLIFE PHARMA INTERNATIONAL INC.

(Formerly SPT Sulphur Polymer Technologies Inc.)

CONDENSED INTERIM STATEMENTS OF FINANCIAL POSITION

(Expressed in Canadian dollars)

As at

	Dec. 31, 2015	March 31, 2015
ASSETS		
Current		
Cash and equivalents	\$ 164	\$ 70,890
GST receivable	6,475	3,536
Prepaid expenses	3,396	13,862
Due from a related party (Note 6)	65,000	65,000
	<u>75,035</u>	<u>153,288</u>
Non-current		
Promissory note receivable (Note 6)	<u>28,336</u>	<u>26,452</u>
TOTAL ASSETS	\$ <u>103,371</u>	\$ <u>179,740</u>
LIABILITIES		
Current Liabilities:		
Accounts payables and accrued liabilities	\$ 32,373	\$ 15,270
Promissory note payable (Note 4)	2,500	2,500
Loan payable (Note 5)	15,000	15,000
Due to related parties (Note 6)	93,588	-
	<u>143,461</u>	<u>32,770</u>
SHAREHOLDERS' EQUITY (DEFICIENCY)		
Capital stock (Note 8)	447,500	447,500
Contributed surplus (Note 8)	8,050	8,050
Deficit	(495,640)	(308,580)
	<u>(40,090)</u>	<u>146,970</u>
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIENCY)	\$ <u>103,371</u>	\$ <u>179,740</u>
Nature and Continuance of Operations (Note 1)		

Approved and authorized for issue by the Board of Directors on February 29, 2015:

"Stan Lis"
Stan Lis, Director

"Casey Forward"
Casey Forward, Director

The accompanying notes are an integral part of these Condensed Interim Financial Statements

LEENLIFE PHARMA INTERNATIONAL INC.

(Formerly SPT Sulphur Polymer Technologies Inc.)

CONDENSED INTERIM STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Expressed in Canadian dollars)

For the periods

	Three Months Ended		Nine Months Ended	
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
EXPENSES				
Bank charges	\$ 133	\$ 53	\$ 332	\$ 499
Consulting	30,000	75,148	52,000	79,148
Filing and transfer fees	12,235	11,949	18,432	22,918
Legal	4,194	26,066	4,194	26,066
Management fees	36,000	-	36,000	-
Office and miscellaneous	10,378	20,956	23,480	20,956
Professional fees	6,702	1,264	22,175	2,318
Travel and promotion	27,600	10,362	32,330	10,362
	127,242	145,798	188,943	162,267
Other Items				
Impairment of investment	-	2,500	-	2,500
Interest income	(630)	-	(1,883)	-
	(630)	2,500	(1,883)	2,500
Net (loss) and comprehensive (loss) for the year	\$ (126,612)	\$ (148,298)	\$ (187,060)	\$ (164,767)
Basic and diluted loss per common share	\$ (0.01)	\$ (0.03)	\$ (0.01)	\$ (0.03)
Weighted average number of common shares outstanding	19,133,334	5,588,335	19,133,334	5,588,335

The accompanying notes are an integral part of these Condensed Interim Financial Statements

LEENLIFE PHARMA INTERNATIONAL INC.

(Formerly SPT Sulphur Polymer Technologies Inc.)

CONDENSED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIENCY)

(Expressed in Canadian dollars)

	Number of Outstanding Shares	Share Capital	Contributed Surplus	Deficit	Total Shareholders' Deficiency
		\$	\$	\$	\$
Balance at March 31, 2015	19,133,334	447,500	8,050	(308,580)	146,970
Net loss for the period	-	-	-	(187,060)	(187,060)
Balance at December 31, 2015	19,133,334	447,500	8,050	(495,640)	(40,090)
<hr/>					
Balance at March 31, 2014	10	100	-	(2,519)	(2,419)
Net loss for the period	-	-	-	(164,767)	(164,767)
Incorporator shares cancelled (Note 8)	(10)	(100)	-	-	(100)
Shares issued in spin-off (Note 8)	2,633,334	5,000	-	-	5,000
Shares for cash in private placement	15,000,000	300,000	-	-	300,000
Shares for cash in private placement	1,500,000	150,000	-	-	150,000
Share issue expense - cash	-	(7,500)	-	-	(7,500)
Balance at December 31, 2014	19,133,334	447,500	-	(167,286)	280,214

The accompanying notes are an integral part of these Condensed Interim Financial Statements

LEENLIFE PHARMA INTERNATIONAL INC.
(Formerly SPT Sulphur Polymer Technologies Inc.)
CONDENSED INTERIM STATEMENTS OF CASH FLOWS
(Expressed in Canadian dollars)
For the Period Ended

	December 31, 2015	December 31, 2014
	\$	\$
CASH FLOWS PROVIDED BY (USED FOR):		
OPERATING ACTIVITIES		
Loss for the period	(187,060)	(164,767)
Adjusted for:		
Accrued interest income	(1,883)	-
Net change in non-cash working capital items:		
Subscription receivable	-	100
GST receivable	(2,939)	(1,448)
Prepaid	10,465	-
Short-term loan payable	-	(50,000)
Accounts payable and accrued liabilities	17,103	18,537
Net cash provided by (used in) operating activities	(164,314)	(197,578)
Financing activities		
Shares issuance on incorporation	-	-
Shares issued for spin-off	-	5,000
Shares issued for cash in private placement net costs	-	447,400
Loan received	-	15,000
Advance from the related parties	93,588	(5,000)
Net cash provided by financing activities	93,588	462,400
Investing activities		
Licence - Sulstar Technologies	-	(25,000)
Long-term loan	-	(25,000)
Investments	-	(15,000)
Deposit on option	-	(2,500)
Net cash used in investing activities	-	(67,500)
Change in cash	(70,726)	197,322
Cash, beginning of the period	70,890	4,981
Cash, end of the period	164	235,433
Cash paid during the period for interest expense	\$ -	\$ -
Cash paid during the period for income taxes	\$ -	\$ -

The accompanying notes are an integral part of these Condensed Interim Financial Statements

LEENLIFE PHARMA INTERNATIONAL INC.
(Formerly SPT Sulphur Polymer Technologies Inc.)
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
December 31, 2015
(Expressed in Canadian dollars)
(Unaudited - See Notice)

1. NATURE AND CONTINUANCE OF OPERATIONS

The Company was incorporated as a numbered company under the laws of the Province of British Columbia on January 12, 2014. Pursuant to a plan of arrangement (the "Arrangement") dated January 14, 2014, between the Company and Vinergy Resources Ltd. ("Vinergy"), the Company acquired from Vinergy a business interest and \$5,000 in cash as part of the Arrangement.

As consideration for the business interest and the cash, the Company issued to Vinergy 2,633,334 common shares in its capital, which shares were distributed by Vinergy to its shareholders. Vinergy completed the share distribution on June 18, 2014.

With the completion of the share distribution, on June 18, 2014, the Company became a reporting issuer in British Columbia, Alberta and Ontario and changed its name on August 1, 2014, to SPT Sulphur Polymer Technologies Inc. On December 17, 2014 the Company was listed and began trading on the Canadian Securities Exchange ("CSE") under the symbol "SEE".

In July, 2015, the Company entered into an agreement to acquire a 90 interest in a Polish private company that had developed a process to isolate omega-3 fatty acids from flax seeds. The acquisition constituted a change of business for the Company for which final approval was received from the CSE on December 2, 2015 and the transaction was formally completed on February 18, 2016. In connection with the change of business, on December 3, 2015 the Company changed its name to LeenLife Pharma International Inc. and commenced trading on the CSE under the symbol "LLP".

The head office and registered and records office for the Company is located at Suite 488 - 625 Howe Street, Vancouver, British Columbia, V6C 2T6,

These financial statements have been prepared in accordance with International Financial Reporting Standards("IFRS") assuming the Company will continue on a going-concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business rather than through a process of forced liquidation. The Company's continuing operations, as intended, and its financial success may be dependent upon the extent to which it can successfully develop its business and raise additional financing as required.

Any business the Company proposes to undertake may take some time to achieve profitable operation and the amount of resulting income, if any, is difficult to determine with any certainty. As a development stage company, at December 31, 2015, the Company had not yet achieved profitable operations and has accumulated losses of \$495,640 since its inception and expects to incur further losses in the development of its business, all of which casts significant doubt about the Company's ability to continue as a going concern.

These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

LEENLIFE PHARMA INTERNATIONAL INC.
(Formerly SPT Sulphur Polymer Technologies Inc.)
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
December 31, 2015
(Expressed in Canadian dollars)
(Unaudited - See Notice)

2. BASIS OF PRESENTATION

Statement of compliance

These financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and interpretations of the International Financial Reporting Interpretations Committee ("IFRIC").

Basis of presentation

These financial statements are presented in Canadian dollars, which is the Company's functional and reporting currency and have been prepared on the historical cost basis except for certain financial instruments, which are measured at fair value, as explained in the accounting policies set out in Note 3. In addition, these financial statements have been prepared using the accrual basis of accounting, except for certain cash flow information

3. SIGNIFICANT ACCOUNTING POLICIES

a. Significant accounting judgments and estimates

The preparation of these financial statements requires management to make judgments and estimates that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual outcomes could differ from these judgments and estimates. The financial statements include judgments and estimates which, by their nature, are uncertain. The impacts of such judgments and estimates are pervasive throughout the financial statements, and may require accounting adjustments based on future occurrences. Revisions to accounting estimates are recognized in the period in which the estimate is revised and the revision affects both current and future periods. Accounts which require management to make material estimates and significant assumptions in determining amounts recorded include valuation of share-based transactions and provision for deferred income tax.

Judgments made by management that have the most significant effect on the financial statements are discussed in Notes 3d), 3e), 3f) and 3i).

b. Cash and cash equivalents

Cash and cash equivalents are comprised of cash in banks, and all short-term investments that are highly liquid in nature, cashable, and have an original maturity date of three months or less. As at December 31, 2015, there is \$Nil included as cash equivalents.

c. Shared-based payments

Pursuant to the Company's option plan ("Option Plan"), the Company may grant stock options to directors, officers and employees for the purchase of the capital stock of the Company. Included in the Option Plan are provisions that provide that the number of common shares reserved for issuance will not exceed 10% of the issued and outstanding common shares of the Company. At the discretion of the

LEENLIFE PHARMA INTERNATIONAL INC.
(Formerly SPT Sulphur Polymer Technologies Inc.)
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
December 31, 2015
(Expressed in Canadian dollars)
(Unaudited - See Notice)

3. SIGNIFICANT ACCOUNTING POLICIES (continued)

c. Shared-based payments (continued)

Board of Directors of the Company, options granted under the Option Plan can have a maximum exercise term of 5 years from the date of grant. Vesting terms will be determined at the time of grant by the Board of Directors.

The fair value of the options is measured at grant date, using the Black-Scholes option pricing model, and is recognized over the period that the employees earn the options. The fair value is recognized as an expense with a corresponding increase in equity. The amount recognized as expense is adjusted to reflect the number of share options expected to vest.

d. Deferred income taxes

Deferred income tax assets and liabilities are recognized for deferred income tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using the enacted or substantively enacted tax rates expected to apply when the asset is realized or the liability settled. The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in income in the period that substantive enactment occurs. To the extent that the Company does not consider it more likely than not that a deferred income tax asset will be recovered, the deferred income tax assets is reduced. Deferred income tax assets and liabilities are offset only if a legally enforceable right exists to offset current tax assets against liabilities and the deferred tax assets and liabilities relate to income taxes levied by the same taxation authority on the same taxable entity.

e. Financial instruments

Financial instruments are defined as any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. The Company recognizes financial assets and financial liabilities when it becomes a party to the contractual provisions of the instrument.

Financial instruments at fair value through profit or loss (FVTPL).

Financial instruments are classified as FVTPL when they are held for trading. A financial instrument is held for trading if it was acquired for the purpose of selling in the near term. Financial instruments classified as FVTPL are stated at fair value with any changes in fair value recognized in earnings for the period.

Loans and receivables

Loans and receivables are financial assets with fixed or determinable payments that are not quoted in an active market. Subsequent to initial recognition, these financial assets are recorded at amortized cost using the effective interest method less any impairment.

Available-for-sale financial assets

Available-for-sale are non-derivative financial assets that are designated as available-for-sale or that are not classified in any other financial asset categories. Subsequent to initial recognition, changes in fair value, other than impairment losses, are recognized in other comprehensive income

LEENLIFE PHARMA INTERNATIONAL INC.
(Formerly SPT Sulphur Polymer Technologies Inc.)
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
December 31, 2015
(Expressed in Canadian dollars)
(Unaudited - See Notice)

3. SIGNIFICANT ACCOUNTING POLICIES (continued)

e. Financial instruments (continued)

(loss) and presented in the fair value reserve in shareholders' equity. When the financial assets are sold or an impairment write-down is required, losses accumulated in the fair value reserve recognized in shareholders' equity are included in profit or loss.

Financial liabilities

Financial liabilities are initially recorded at fair value, net of transaction costs, and are subsequently measured at amortized cost using the effective interest method. The Company's accounts payable, accrued liabilities and advance from parent company are classified as financial liabilities. Transaction costs incurred on initial recognition of financial instruments classified as loans and receivables and other financial liabilities are included in the initial fair value amount.

Financial assets are derecognized when the contractual rights to the cash flows from the asset expire. Financial liabilities are derecognized only when the Company's obligations are discharged, cancelled or they expire.

The Company has classified its financial instruments as follows:

<u>Financial Instrument</u>	<u>Classification</u>
Cash and cash equivalents	FVTPL
GST receivable and prepaid expenses	Loans and receivables
Due from a related party	Loans and receivables
Accounts payable and accrued liabilities	Other liabilities
Promissory note payable	Other liabilities
Loan payable	Other liabilities

Financial instruments recorded at fair value on the statement of financial position are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels: Level 1 – valuation based on quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 – valuation techniques based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and Level 3 – valuation techniques using inputs for the asset or liability that are not based on observable market data (unobservable inputs).

f. Impairment

Non-financial assets

The carrying amounts of the Company's non-financial assets, other than deferred income tax assets, are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the assets' recoverable amount is estimated. For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or group of assets (the "cash-generating unit").

LEENLIFE PHARMA INTERNATIONAL INC.
(Formerly SPT Sulphur Polymer Technologies Inc.)
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
December 31, 2015
(Expressed in Canadian dollars)
(Unaudited - See Notice)

3. SIGNIFICANT ACCOUNTING POLICIES (continued)

f. Impairment (continued)

An impairment loss is recognized if the carrying amount of a cash-generating unit exceeds its estimated recoverable amount. The recoverable amount of an asset or a cash-generating unit is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cost flows are discounted to their present value using a pre-tax discount rate that reflects current market assessment of the time value of money and the risks specific to the assets. Impairment losses are recognized in net income (loss).

Impairment losses recognized in prior years are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation, if no impairment loss has been recognized.

Financial assets

A financial asset not carried at fair value through profit or loss is assessed at each reporting date to determine whether there is objective evidence that it is impaired. A financial asset is impaired if objective evidence indicates that a loss event has occurred after the initial recognition of the asset, and that the loss event had a negative effect on the estimated future cash flows of that asset that can be estimated reliably.

An impairment loss in respect of a financial asset measured at amortized cost is calculated as the difference between its carrying amount and the present value of the estimated future cash flows discounted at the asset's original effective interest rate. Losses are recognized in net income (loss) and reflected in an allowance account against receivables. When a subsequent event causes the amount of impairment loss to decrease, the decrease in impairment loss is reversed through net income (loss).

g. Comprehensive income (loss)

Comprehensive income (loss) is the change in the Company's net assets that results from transactions, events and circumstances from sources other than the Company's shareholders and includes items that are not included in net profit. Other comprehensive income (loss) consists of changes to unrealized gain and losses on available for sale financial assets, changes to unrealized gains and losses on the effective portion of cash flow hedges and changes to foreign currency translation adjustments of self-sustaining foreign operations during the period. Comprehensive income (loss) measures net earnings for the period plus other comprehensive income (loss). Amounts reported as other comprehensive income (loss) are accumulated in a separate component of shareholders' equity as Accumulated Other Comprehensive Income (Loss). The Company has not had other comprehensive income (loss) since inception and accordingly, a statement of comprehensive income (loss) has not been presented.

h. Earnings (loss) per share

Basic earnings (loss) per share is computed by dividing the net earnings (loss) available to common shareholders by the weighted average number of shares outstanding during the reporting period. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the

LEENLIFE PHARMA INTERNATIONAL INC.
(Formerly SPT Sulphur Polymer Technologies Inc.)
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
December 31, 2015
(Expressed in Canadian dollars)
(Unaudited - See Notice)

3. SIGNIFICANT ACCOUNTING POLICIES (continued)

h. Earnings (loss) per share (continued)

weighted average share outstanding is increased to include additional shares for the assumed exercise of stock options and warrants, if dilutive. The number of additional shares is calculated by assuming that outstanding stock options and warrants were exercised and that the proceeds from such exercises were used to acquire common stock at the average market price during the reporting periods.

i. Provisions

Provisions are recorded when a present legal or constructive obligation exists as a result of past events where it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation, and a reliable estimate of the amount of the obligation can be made.

The amount recognized as a provision is the best estimate of the consideration required to settle the present obligation at statement of financial position date, taking into account the risks and uncertainties surrounding the obligation. Where a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows. The increase in the obligation due to the passage of time is recognized as finance expense. When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, the receivable is recognized as an asset if it is virtually certain that reimbursement will be received and the amount receivable can be measured reliably.

j. Accounting standards issued but not yet effective

The following new standards, amendments to standards and interpretations have been issued but are not effective during the period ended December 31, 2015:

- IAS 1 The amendment improves the effectiveness of presentation and disclosure in financial reports with the objective of reducing immaterial note disclosure. The amendments are effective for annual periods beginning on or after January 1, 2016.

- IAS 16 and IAS 38 The amendments clarify that the use of revenue-based methods to calculate the depreciation of an asset is not appropriate. The amendments are effective for annual periods beginning on or after January 1, 2016.

- IFRS 9 New standard that replaces IAS 39 for classification and measurement of financial instruments. IFRS 9 simplifies the mixed measurement model and establishes two primary measurement categories for financial assets: amortized cost and fair value. The new standard also requires a single impairment method to be used, replacing the multiple impairment methods in IAS 39. IFRS 9 is effective for annual periods beginning on or after January 1, 2018.

LEENLIFE PHARMA INTERNATIONAL INC.
(Formerly SPT Sulphur Polymer Technologies Inc.)
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
December 31, 2015
(Expressed in Canadian dollars)
(Unaudited - See Notice)

3. SIGNIFICANT ACCOUNTING POLICIES (continued)

j. Accounting standards issued but not yet effective (continued)

- IFRS 15 New standard that establish principles for reporting the nature, amount, timing, and uncertainty of revenue and cash flows arising from an entity's contracts with customers. It provides a single model in order to depict the transfer of promised goods or services to customers. IFRS 15 is effective for annual periods beginning on or after January 1, 2018.

The Company is currently in the process of reviewing the standards to determine the impact on the consolidated financial statements.

Other accounting standards or amendments to existing accounting standards that have been issued but have future effective dates are either not applicable or are not expected to have a significant impact on the Company's financial statements.

i. Segment reporting

A reportable segment, as defined by 'IFRS 8 Operating Segments', is a distinguishable business or geographical component of the Company, which are subject to risks and rewards that are different from those of other segments. The Company considers its primary reporting format to be business segments. As at December 31, 2015, the Company considers that it has one reportable business segment, the license to manufacture, sell and distribute products under the Sulstar license.

4. PROMISSORY NOTE

As at December 31, 2015, the Company had an obligation under a promissory note in the amount of \$2,500. The Note is non-interest bearing, unsecured and due on demand to TBG Capital Inc.

5. LOAN PAYABLE

The Company has a loan payable of \$15,000 to a third party. The loan is unsecured, without interest and due on demand.

6. LOANS RECEIVABLE

(a) Promissory note receivable

The Company has advanced a loan of \$25,000 to an arms' length company. The loan is repayable on September 30, 2016 and accrues interest at the rate of 10% per annum, annually in arrears. As at December 31, 2015, interest of \$1,883 was accrued with respect to the current period bringing the total accrued interest to \$3,336.

LEENLIFE PHARMA INTERNATIONAL INC.
(Formerly SPT Sulphur Polymer Technologies Inc.)
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
December 31, 2015
(Expressed in Canadian dollars)
(Unaudited - See Notice)

6. LOANS RECEIVABLE (continued)

(b) Due from a related parties

- (i) The Company has advanced an amount of \$65,000 to Leucadia Finance Partners Inc., a company the majority of whose directors are also directors of the Company. The loan is unsecured, without interest and due on demand;
- (ii) At December 31, 2015, the Company had a total of \$93,588 outstanding as payable to related parties. This total represents amounts due to directors of the Company for management and consulting fees, accrued and not paid and/or expenses incurred by the directors on behalf of the Company for which the directors have not been reimbursed. These amounts are unsecured, without interest and with no fix terms of repayment.

7. SULSTAR LICENCE

Sulstar Licence

On July 17th, 2014 the Company acquired a license from Sulstar Technologies Inc., a British Columbia corporation, for a patented technology for converting waste sulphur into unique granulated thermoplastic asphalt binder and a modified sulphur polymer concrete marketed under the names of Sulstar and Sulconcrete, respectively, for the provinces of British Columbia, Alberta, Saskatchewan and the Yukon Territory, in consideration of \$25,000 cash (paid) and a 2% royalty on all sales. The license has a five year term (expires on August 14, 2019) and is renewable based on performance.

During the year ended March 31, 2015, the Company recorded impairment in the amount of \$25,000 as the Company had no immediate plans to conduct further business on this project.

8. CAPITAL STOCK

Authorized: An unlimited number of common shares, without par value.

There were no transactions in the Company's capital stock during the nine months ended December 31, 2015.

The following transactions took place during the year ended March 31, 2015:

On August 29th, 2014 the Company consolidated its share capital on a basis of 10 old shares for one new share. All mention of shares in these financial statements has been adjusted retroactively. As discussed in Note 1, the Company issued 2,633,334 post consolidation common shares to Vinergy in June of 2014 and Vinergy re-distributed these shares to its shareholders as of the record date of June 5, 2014. The aggregate fair value of these shares in the amount of \$5,000 was based on the fair value estimates of assets transferred from Vinergy to the Company. On January 30, 2014, Vinergy transferred \$5,000 cash and assigned the Contract of Purchase and Sale valued at \$Nil to the Company.

On September 23, 2014 the Company closed a \$300,000 private placement. The financing was for 15,000,000 common shares at \$0.02 each.

LEENLIFE PHARMA INTERNATIONAL INC.
(Formerly SPT Sulphur Polymer Technologies Inc.)
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
December 31, 2015
(Expressed in Canadian dollars)
(Unaudited - See Notice)

8. CAPITAL STOCK (continued)

On December 8, 2014 the Company closed a \$150,000 private placement. The financing was for 1,500,000 common shares at \$0.10 each. Finder's fee of \$7,500 was paid.

Stock Options:

The Company has adopted an incentive stock option plan (the "Option Plan") which provides that the Board of Directors of the Company may from time to time, in its discretion, and in accordance with the applicable stock exchange's requirements, grant to directors, officers, employees and consultants to the Company, non-transferable options to purchase common shares. Pursuant to the Option Plan, the number of common shares reserved for issuance will not exceed 10% of the issued and outstanding common shares of the Company. Options granted under the Option Plan can have a maximum exercise term of 5 years from the date of grant. Vesting terms will be determined at the time of grant by the Board of Directors.

There were no grants or exercises of options during the nine months ended December 31, 2015.

On September 29, 2014, the Company granted 800,000 options to officers, directors and consultants. They have an exercise price of \$0.10 for a period of five years from the date of issue. The options were fully vested upon issue.

During the year ended March 31, 2015, the Company recognized \$8,050 (2014 - \$nil) in compensation upon issuance of 800,000 stock options (2014 - nil). The fair values of these options were determined using the Black-Scholes option pricing model with the following assumptions.

	March 31, 2015
Risk-free interest rate	1.62%
Experienced life of options	5
Annualized volatility	100.00%
Dividend rate	-

As at December 31, 2015, the Company had no stock options outstanding and exercisable.

A summary of the status of the Company's stock options as at December 31, 2015 and March 31, 2015, and changes during those periods is presented below:

	Options Outstanding	Weighted Average Exercise Price	Remaining Contractual Life Years
Balance, March 31, 2014	-	\$ -	-
Granted during fiscal 2015	800,000	\$0.10	5.00
Balance, March 31, 2015	800,000	\$0.10	4.50
Cancelled in period	(800,000)	-	-
Balance, December 31, 2015	-	-	-

LEENLIFE PHARMA INTERNATIONAL INC.
(Formerly SPT Sulphur Polymer Technologies Inc.)
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
December 31, 2015
(Expressed in Canadian dollars)
(Unaudited - See Notice)

9. Capital Disclosures

The Company's objectives when managing capital is to safeguard its ability to continue as a going concern, so that it can provide returns for shareholders and benefits for other stakeholders. The Company considers the items included in shareholders' equity and cash as capital. The Company manages the capital structure and makes adjustments to it in response to changes in economic conditions and the risk characteristics of the underlying assets. The Company's primary objective with respect to its capital management is to ensure that it has sufficient cash resources to fund the development of the real estate development Business. To secure the additional capital necessary to pursue these plans, the Company intends to raise additional funds through the equity or debt financing. The Company is not subject to any capital requirements imposed by a regulator.

10. FINANCIAL INSTRUMENTS

The Company's financial instruments consist of cash, investment in securities, short term loan, due from(to) a related party, accounts payable and accrued liabilities and property option payable. Cash is stated at fair value and classified within Level 1 of the fair value hierarchy. The fair values of accrued liabilities approximate their carrying values due to their short- term nature of these instruments.

The Company's risk exposures and the impact on the Company's financial instruments are summarized below:

Strategic and operational risks are risks that arise if the Company fails to develop the real estate development Business. These strategic opportunities or threats arise from a range of factors which might include changing economic and political circumstances and regulatory approvals and competitor actions. The risk is mitigated by consideration of other potential development opportunities and challenges which management may undertake.

The Company's credit risk was primarily attributable to bank balances and subscriptions receivable. The Company limits its credit exposure on cash held in bank accounts firstly by holding its key transactional bank accounts with banks of international financial institutions. Subscriptions receivable is due from the parent company and management believes that the credit risk to be minimal.

Liquidity risk is the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities. The Company's approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. As at December 31, 2015, the Company had a cash balance of \$164 and current liabilities of \$133,461. All of the Company's financial liabilities have contractual maturities of less than 30 days, and are subject to normal trade terms. Management is considering different alternatives to secure adequate debt or equity financing to meet the Company short-term and long-term cash requirements.

Interest risk is the risk that the fair value or future cash flows will fluctuate as a result of changes in market risk. The Company's sensitivity to interest rates is currently immaterial.

LEENLIFE PHARMA INTERNATIONAL INC.
(Formerly SPT Sulphur Polymer Technologies Inc.)
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
December 31, 2015
(Expressed in Canadian dollars)
(Unaudited - See Notice)

10. FINANCIAL INSTRUMENTS (continued)

Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Company holds no financial instruments that are denominated in a currency other than Canadian dollar. Accrued liabilities are denominated in Canadian currency. Therefore, the Company's exposure to currency risk is minimal.

11. RELATED PARTY TRANSACTIONS

During the nine months ended December 31, 2015, the Company entered into the following transactions with related parties:

- (a) Management fees of \$36,000 were paid or accrued to be paid to Stan Lis, CEO and a director of the Company;
- (b) Consulting fees of \$30,000 were paid or accrued to be paid to Casey Forward, CFO and a director of the Company;
- (c) The Company has amounts payable to related parties at December 31, 2015 as described in Note 6(b)(ii).

During the year ended March 31, 2015 the following transactions were entered into:

- a) \$3,232 in accounting fees were charged by a former director of the Company (resigned on May 20, 2015); and
- b) the Company advanced a loan to a company with common directors as described in Note 6(b)(i)

As at March 31, 2015, the Company owed an advance of \$nil (March 31, 2014 - \$5,000 to) Vinergy and also had a subscription receivable of \$nil (March 31, 2014 - \$100) to be received from Vinergy.

All related party transactions are in the normal course of operations and have been measured at the agreed to amounts, which is the amount of consideration established and agreed to by the related parties.

12. SUBSEQUENT EVENTS

In July, 2015, the Company entered into a share purchase agreement to acquire a 90-per-cent interest in a Polish private company, LeenLife Pharma SA, which has developed a process to isolate omega-3 fatty acids from flax seeds. The purchase price is comprised of 12,232,788 common shares of the Company at a deemed issuance price of \$0.1875 per share for an aggregate value of \$2,293,648 and \$563,044 in cash consideration due by January 31, 2016. The Share Purchase Agreement received final approval from the Canadian Securities Exchange (the "CSE") on December 2, 2015. In anticipation of closing the transaction, the Company changed its name to LeenLife Pharma International Inc. on December 3, 2015. Several delays were encountered in closing the transaction, which was finally completed on February 18, 2016. As part of closing, it was agreed that the payment date for the cash consideration be extended to May 31, 2016.